1
Country: Australia | Funding: $453M
AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics. Its lead asset, ADVC001, is currently in a phase 2 trial for metastatic prostate cancer. It's a lutetium-based alpha emitter, which breaks both strands of DNA, a wound much harder for cancer to bounce back from. It can be delivered, lead to double-stranded DNA breaks of the tumor cells in a highly targeted way, and then quickly be gone, which could minimize the accumulation in surrounding healthy tissues.
AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics. Its lead asset, ADVC001, is currently in a phase 2 trial for metastatic prostate cancer. It's a lutetium-based alpha emitter, which breaks both strands of DNA, a wound much harder for cancer to bounce back from. It can be delivered, lead to double-stranded DNA breaks of the tumor cells in a highly targeted way, and then quickly be gone, which could minimize the accumulation in surrounding healthy tissues.
2
Country: USA | Funding: $418M
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.
3
Country: USA | Funding: $331M
Aktis Oncology develops radiopharmaceutical treatments for solid tumors.
Aktis Oncology develops radiopharmaceutical treatments for solid tumors.
4
Country: Canada | Funding: $259M
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
5
Country: USA | Funding: $250M
Mariana Oncology designs radiopharmaceuticals to pierce solid tumors better than antibodies and deliver optimized high radiation activity doses without the side effects tied to chemotherapy and toxin-based strategies.
Mariana Oncology designs radiopharmaceuticals to pierce solid tumors better than antibodies and deliver optimized high radiation activity doses without the side effects tied to chemotherapy and toxin-based strategies.
6
Country: USA | Funding: $245M
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.
7
Country: Canada | Funding: $148.3M
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
8
Country: USA | Funding: $135M
Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.
Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.
9
Country: USA | Funding: $130M
Convergent Therapeutics develops radiopharmaceuticals for the treatment of prostate cancer. These are radioantibodies that deliver alpha-emitting agents, which carry the radioactive payload directly to the cancer cells, making radiation therapy more targeted and effective. The short-acting nature of these alpha-emitting agents minimizes radiation exposure to healthy adjacent cells and tissue. Each radioantibody is created through careful selection of an antibody with high affinity for a specific cancer target. The company's flagship drug, CONV01-α, is a radioantibody labeled with actinium-225, with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients.
Convergent Therapeutics develops radiopharmaceuticals for the treatment of prostate cancer. These are radioantibodies that deliver alpha-emitting agents, which carry the radioactive payload directly to the cancer cells, making radiation therapy more targeted and effective. The short-acting nature of these alpha-emitting agents minimizes radiation exposure to healthy adjacent cells and tissue. Each radioantibody is created through careful selection of an antibody with high affinity for a specific cancer target. The company's flagship drug, CONV01-α, is a radioantibody labeled with actinium-225, with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients.
10
Country: Denmark | Funding: $52.3M
MedTrace provides 15O water for positron emission tomography (PET) imaging. The startup’s platform consists of an automated hardware system for producing, dosing, and injecting 15O water and analytical software for image processing.
MedTrace provides 15O water for positron emission tomography (PET) imaging. The startup’s platform consists of an automated hardware system for producing, dosing, and injecting 15O water and analytical software for image processing.
11
Country: Israel | Funding: $33.1M
Starget Pharma is developing a somatostatin-based targeted cancer therapy platform. It combines therapeutic drugs with radioactive isotopes, minimizing damage to healthy tissue. One of the key advantages of this approach is the use of the same molecular platform for both diagnosis and treatment: first, the molecule is administered along with a diagnostic isotope to assess tumor uptake using imaging. If imaging confirms strong tumor uptake, the same molecule is combined with a more potent therapeutic isotope to deliver targeted therapy. The own AI platform enables faster discovery and development of highly accurate radiopharmaceuticals. The company is conducting clinical trials of this technology for the treatment of sarcoma, skin cancer, liver cancer and neuroendocrine tumors.
Starget Pharma is developing a somatostatin-based targeted cancer therapy platform. It combines therapeutic drugs with radioactive isotopes, minimizing damage to healthy tissue. One of the key advantages of this approach is the use of the same molecular platform for both diagnosis and treatment: first, the molecule is administered along with a diagnostic isotope to assess tumor uptake using imaging. If imaging confirms strong tumor uptake, the same molecule is combined with a more potent therapeutic isotope to deliver targeted therapy. The own AI platform enables faster discovery and development of highly accurate radiopharmaceuticals. The company is conducting clinical trials of this technology for the treatment of sarcoma, skin cancer, liver cancer and neuroendocrine tumors.
12
Country: Germany
Navigo Proteins develops novel radio-conjugates. The startup engineers Affilin, artificial proteins designed to selectively bind antigens, radio conjugates.
Navigo Proteins develops novel radio-conjugates. The startup engineers Affilin, artificial proteins designed to selectively bind antigens, radio conjugates.
